Abstract
The first mention concerning occurrence of cardiometabolic risk factors together appeared 100 years ago. Metabolic syndrome brings 5times higher risk for type 2 diabetes development and 2-3tímes higher cardiovascular (CV) risk in comparison to the subjects without that syndrome.
Healthy life habits and rational pharmacotherapy of hypertension, dyslipidemia and hyperglycemia represent an effective way for high cardiometabolic risk reduction. The problem are patient's low adherence and persistence to the recommendation and pharmacotherapy.
Right now polypill (fixed combination of antihypertensives and lipid modifying drugs) are solving in the CV disease prevention. However suficient evidence exist in the secondary CV prevention, some gap of knowledge is persisting in the primary CV prevention.
Right combination of drugs in the polypill might be a suitable solving of CV disease and diabetes prevention for the patients with metabolic syndrome.